WooGene B&G Co. Ltd (018620) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.015x

Based on the latest financial reports, WooGene B&G Co. Ltd (018620) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩987.57 Million ≈ $669.26K USD) by net assets (₩66.90 Billion ≈ $45.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of WooGene B&G Co. Ltd to measure how much of total assets are equity-financed.

WooGene B&G Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how WooGene B&G Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 018620 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

WooGene B&G Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of WooGene B&G Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
City Sports and Recreation Public Company Limited BK:CSR	0.010x
Argosy Minerals Ltd AU:AGY	-0.008x
Taewoong Logistics Co.Ltd KQ:124560	-0.053x
Beneficient Class A Common Stock NASDAQ:BENF	0.246x
Lunnon Metals Ltd AU:LM8	-0.119x
Adveritas Ltd AU:AV1	-1.106x
Ege Seramik Sanayi ve Ticaret AS IS:EGSER	-0.103x
LGL Group Inc NYSE MKT:LGL	0.011x

Annual Cash Flow Conversion Efficiency for WooGene B&G Co. Ltd (2011–2024)

The table below shows the annual cash flow conversion efficiency of WooGene B&G Co. Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see 018620 market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩27.79 Billion ≈ $18.83 Million	₩6.78 Billion ≈ $4.60 Million	0.244x	+540.75%
2023-12-31	₩72.33 Billion ≈ $49.02 Million	₩2.76 Billion ≈ $1.87 Million	0.038x	-47.68%
2022-12-31	₩35.32 Billion ≈ $23.93 Million	₩2.57 Billion ≈ $1.74 Million	0.073x	-44.60%
2021-12-31	₩31.14 Billion ≈ $21.11 Million	₩4.09 Billion ≈ $2.77 Million	0.131x	+58.90%
2020-12-31	₩29.85 Billion ≈ $20.23 Million	₩2.47 Billion ≈ $1.67 Million	0.083x	+221.95%
2019-12-31	₩27.27 Billion ≈ $18.48 Million	₩-1.85 Billion ≈ $-1.25 Million	-0.068x	+51.68%
2018-12-31	₩26.51 Billion ≈ $17.97 Million	₩-3.72 Billion ≈ $-2.52 Million	-0.140x	-110.00%
2017-12-31	₩23.04 Billion ≈ $15.61 Million	₩-1.54 Billion ≈ $-1.04 Million	-0.067x	-151.96%
2016-12-31	₩22.14 Billion ≈ $15.00 Million	₩2.85 Billion ≈ $1.93 Million	0.129x	+279.51%
2015-12-31	₩21.90 Billion ≈ $14.84 Million	₩-1.57 Billion ≈ $-1.06 Million	-0.072x	-199.97%
2014-12-31	₩20.67 Billion ≈ $14.01 Million	₩1.48 Billion ≈ $1.00 Million	0.072x	-36.08%
2012-12-31	₩18.56 Billion ≈ $12.58 Million	₩2.08 Billion ≈ $1.41 Million	0.112x	+157.29%
2011-12-31	₩17.74 Billion ≈ $12.02 Million	₩773.08 Million ≈ $523.90K	0.044x	--

About WooGene B&G Co. Ltd

KQ:018620 Korea Pharmaceuticals

Market Cap

$45.84 Million

₩67.64 Billion KRW

Market Cap Rank

#22159 Global

#1346 in Korea

Share Price

₩2605.00

Change (1 day)

-1.14%

52-Week Range

₩670.00 - ₩3400.00

All Time High

₩6913.04